JP7824938B2 - Tyk2阻害剤およびその使用 - Google Patents

Tyk2阻害剤およびその使用

Info

Publication number
JP7824938B2
JP7824938B2 JP2023517268A JP2023517268A JP7824938B2 JP 7824938 B2 JP7824938 B2 JP 7824938B2 JP 2023517268 A JP2023517268 A JP 2023517268A JP 2023517268 A JP2023517268 A JP 2023517268A JP 7824938 B2 JP7824938 B2 JP 7824938B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
stereoisomer
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023517268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541203A5 (cg-RX-API-DMAC7.html
JP2023541203A (ja
Inventor
ジン,ボアン
ドン,チン
フン,ジーン
Original Assignee
アルミス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルミス インコーポレイテッド filed Critical アルミス インコーポレイテッド
Publication of JP2023541203A publication Critical patent/JP2023541203A/ja
Publication of JP2023541203A5 publication Critical patent/JP2023541203A5/ja
Application granted granted Critical
Publication of JP7824938B2 publication Critical patent/JP7824938B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023517268A 2020-09-16 2021-09-16 Tyk2阻害剤およびその使用 Active JP7824938B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063079217P 2020-09-16 2020-09-16
US63/079,217 2020-09-16
PCT/US2021/050649 WO2022060973A1 (en) 2020-09-16 2021-09-16 Tyk2 inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2023541203A JP2023541203A (ja) 2023-09-28
JP2023541203A5 JP2023541203A5 (cg-RX-API-DMAC7.html) 2024-09-17
JP7824938B2 true JP7824938B2 (ja) 2026-03-05

Family

ID=78086111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517268A Active JP7824938B2 (ja) 2020-09-16 2021-09-16 Tyk2阻害剤およびその使用

Country Status (9)

Country Link
US (1) US12679850B2 (cg-RX-API-DMAC7.html)
EP (1) EP4214215A1 (cg-RX-API-DMAC7.html)
JP (1) JP7824938B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230069984A (cg-RX-API-DMAC7.html)
CN (1) CN117279922B (cg-RX-API-DMAC7.html)
AU (1) AU2021345181A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192621A1 (cg-RX-API-DMAC7.html)
IL (1) IL301385A (cg-RX-API-DMAC7.html)
WO (1) WO2022060973A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
CN119487037A (zh) * 2022-03-16 2025-02-18 阿鲁米斯股份有限公司 Tyk2抑制剂及其用途
EP4493281A1 (en) * 2022-03-16 2025-01-22 Alumis Inc. Tyk2 inhibitors and uses thereof
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用
EP4692096A4 (en) 2023-03-31 2026-07-22 Prime Gene Therapeutics Co Ltd MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND ITS USE
WO2024222807A1 (en) * 2023-04-27 2024-10-31 Hangzhou Highlightll Pharmaceutical Co., Ltd Novel macrocyclic heteroaryl derivatives as kinase inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519343A (ja) 2015-07-02 2018-07-19 ティーピー・セラピューティクス・インコーポレイテッドTp Therapeutics,Inc. プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
JP2019530699A (ja) 2016-10-07 2019-10-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Il−12、il−23および/またはifnアルファ応答の調節剤として有用なイミダゾピリダジン化合物
JP2020514409A (ja) 2017-01-25 2020-05-21 ターニング・ポイント・セラピューティクス・インコーポレイテッドTurning Point Therapeutics,Inc. ジアリール大環状化合物を含む併用療法
WO2020163778A1 (en) 2019-02-07 2020-08-13 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
JP2022529311A (ja) 2019-03-26 2022-06-21 ベンティックス バイオサイエンシーズ,インク. Tyk2偽キナーゼリガンド
JP7586829B2 (ja) 2019-03-11 2024-11-19 アルミス インコーポレイテッド Tyk2阻害剤およびその使用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1351691A4 (en) 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
US20060281763A1 (en) 2005-03-25 2006-12-14 Axon Jonathan R Carboxamide inhibitors of TGFbeta
US7517882B2 (en) 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
KR20100132550A (ko) 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드
EP2361902A4 (en) 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
MX2011011875A (es) 2009-05-08 2011-12-08 Astellas Pharma Inc Compuesto de carboxamida heterociclica diamino.
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
EP2975027A1 (en) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
AU2011323484B2 (en) 2010-11-01 2016-10-06 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as Syk modulators
CN102250065B (zh) 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
PT2760453T (pt) 2011-09-30 2016-08-02 Ipsen Pharma Sas Inibidores macrocíclicos da cinase lrrk2
KR20140108594A (ko) 2012-01-10 2014-09-11 에프. 호프만-라 로슈 아게 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
US9701689B2 (en) 2012-11-30 2017-07-11 Kyowa Hakko Kirin Co., Ltd. Substituted pyridines and pyridazines as CCR10 receptor inhibitors
WO2014140299A1 (en) 2013-03-15 2014-09-18 Oncodesign S.A Macrocyclic rip2 kinase inhibitors
JP6484555B2 (ja) 2013-08-29 2019-03-13 京都薬品工業株式会社 新規芳香族化合物およびその用途
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
AU2014360446A1 (en) 2013-12-05 2016-06-09 Pharmacyclics, Llc Inhibitors of Bruton's tyrosine kinase
WO2015112806A2 (en) 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
WO2015123453A1 (en) 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
CN105111151B (zh) 2015-04-17 2018-09-28 成都理工大学 作为PPAR-γ调节剂的氨基嘧啶衍生物
BR112017025986A2 (pt) 2015-06-02 2018-08-14 Pharmacyclics Llc inibidores de tirosina quinase de bruton.
BR112018000297A2 (pt) 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
WO2017015367A1 (en) 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
KR102782807B1 (ko) * 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
EP3405464B1 (en) 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
AU2017302019A1 (en) 2016-07-28 2019-02-07 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018112027A1 (en) 2016-12-14 2018-06-21 Development Center For Biotechnology Antibody-drug conjugates and uses thereof
CN106866660B (zh) 2017-02-15 2019-05-17 上海天马有机发光显示技术有限公司 电子传输材料、包含其的oled显示面板和电子设备
AU2018230737B2 (en) 2017-03-08 2022-09-22 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018186366A1 (ja) 2017-04-03 2018-10-11 京都薬品工業株式会社 新規サイクリン依存性キナーゼ8及び/又は19阻害剤
WO2018234345A1 (en) 2017-06-21 2018-12-27 F. Hoffmann-La Roche Ag PYRAZOLO [1,5A] PYRIMIDINE DERIVATIVES AS MODULATORS OF IRAK4
PT3658148T (pt) 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
KR102619444B1 (ko) 2017-08-23 2023-12-29 치아타이 티안큉 파마수티컬 그룹 주식회사 아미노피라졸 및 피리미딘을 함유하는 마크로사이클 및 그의 약학적 조성물 및 용도
WO2019049891A1 (ja) 2017-09-06 2019-03-14 小野薬品工業株式会社 Trk阻害剤とキナーゼ阻害剤の併用による癌治療方法
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
WO2019084499A1 (en) 2017-10-27 2019-05-02 Genea Biocells USA (Holdings), Inc. INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION
CA3081790C (en) 2017-11-10 2023-03-07 Angex Pharmaceutical, Inc. Macrocyclic compounds as trk kinase inhibitors and uses thereof
RS63787B1 (sr) 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti
WO2019144885A1 (zh) 2018-01-23 2019-08-01 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
WO2019165967A1 (zh) 2018-02-28 2019-09-06 南京明德新药研发有限公司 吡唑并嘧啶衍生物及其用途
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
CN109053682B (zh) 2018-07-27 2020-10-27 东南大学 一种tdo小分子抑制剂衍生物及其抗肿瘤偶联物和制备方法
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
CA3126034A1 (en) * 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
KR102943760B1 (ko) 2019-01-28 2026-03-26 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 피리다진 유도체 억제제, 및 그의 제조 방법 및 용도
CN114929226B (zh) 2019-11-08 2024-09-27 温缇克斯生物科学公司 Tyk2假激酶配体
EP4493281A1 (en) * 2022-03-16 2025-01-22 Alumis Inc. Tyk2 inhibitors and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519343A (ja) 2015-07-02 2018-07-19 ティーピー・セラピューティクス・インコーポレイテッドTp Therapeutics,Inc. プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
JP2019530699A (ja) 2016-10-07 2019-10-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Il−12、il−23および/またはifnアルファ応答の調節剤として有用なイミダゾピリダジン化合物
JP2020514409A (ja) 2017-01-25 2020-05-21 ターニング・ポイント・セラピューティクス・インコーポレイテッドTurning Point Therapeutics,Inc. ジアリール大環状化合物を含む併用療法
WO2020163778A1 (en) 2019-02-07 2020-08-13 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
JP7586829B2 (ja) 2019-03-11 2024-11-19 アルミス インコーポレイテッド Tyk2阻害剤およびその使用
JP2022529311A (ja) 2019-03-26 2022-06-21 ベンティックス バイオサイエンシーズ,インク. Tyk2偽キナーゼリガンド

Also Published As

Publication number Publication date
AU2021345181A1 (en) 2023-05-04
JP2023541203A (ja) 2023-09-28
US20230357273A1 (en) 2023-11-09
IL301385A (en) 2023-05-01
WO2022060973A1 (en) 2022-03-24
EP4214215A1 (en) 2023-07-26
CA3192621A1 (en) 2022-03-24
CN117279922A (zh) 2023-12-22
US12679850B2 (en) 2026-07-14
AU2021345181A9 (en) 2024-06-20
KR20230069984A (ko) 2023-05-19
CN117279922B (zh) 2025-12-19

Similar Documents

Publication Publication Date Title
US11731956B2 (en) Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors
JP7586829B2 (ja) Tyk2阻害剤およびその使用
JP2023541203A (ja) Tyk2阻害剤およびその使用
JP2025509596A (ja) Tyk2阻害剤およびその使用
JP2025509594A (ja) Tyk2阻害剤およびその使用
HK40105557B (en) Tyk2 inhibitors and uses thereof
HK40105557A (en) Tyk2 inhibitors and uses thereof
RU2813233C2 (ru) Ингибиторы tyk2 и пути их применения
HK40120037B (en) Tyk2 inhibitors and uses thereof
HK40119624B (en) Tyk2 inhibitors and uses thereof
HK40119624A (en) Tyk2 inhibitors and uses thereof
HK40120037A (en) Tyk2 inhibitors and uses thereof
WO2024127363A1 (en) Tyk2 pseudokinase ligands and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260220

R150 Certificate of patent or registration of utility model

Ref document number: 7824938

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150